Ginkgo biloba Extract EGb 761® in Dementia: Intent-to-treat Analyses of a 24-week, Multi-center, Double-blind, Placebo-controlled, Randomized Trial

 

 Buy Article Permissions and Reprints

In 1996, Kanowski et al. [14] reported about the beneficial effects of ginkgo biloba special extract EGb 761® (240 mg/day) in outpatients with pre-senile and senile primary degenerative dementia of the Alzheimer type (DAT) and multi-infarct dementia (MID) of mild to moderate severity. The comparison of the results of this double-blind, placebo-controlled, randomized, multi-center study with other dementia studies is hampered by the fact that only the responder analysis of the per-protocol (PP) population, which was pre-specified in the protocol as confirmatory analysis, has been published in detail so far. Moreover, cognitive functioning was measured using the Syndrom-Kurztest (SKT), whereas results of other studies are based on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog). Therefore, the conventional intention-to-treat (ITT) analysis of this study is provided with an estimation of ADAS-cog scores based on measured SKT scores. After 24 weeks of treatment, the ITT analysis of the SKT and estimated ADAS-cog scores revealed a mean decrease in the total score by -2.1 (95 % CI: -2.7; -1.5) points and -2.7 (95 % CI: -3.5; -1.9) points, respectively, for the EGb 761® group, which indicates an improvement in cognitive function. On the contrary, the placebo group exhibited only a minimal change of -1.0 (95 % CI: -1.6; -0.3) and -1.3 (95 % CI: -2.0; -0.4) points, respectively. The changes from baseline differed significantly between treatment groups by 1.1 (SKT) and 1.4 (estimated ADAS-cog) points, respectively (P = 0.01). The Clinical Global Impression of Change (CGI, Item 2) favored the EGb 761® group with a mean difference of 0.4 points (P = 0.007). Changes in the rating related to activities of daily living (Nürnberger-Alters-Beobachtungs-Skala, NAB) showed a favorable trend for EGb 761®. A subgroup analysis regarding patients with DAT yielded comparable results. Using a decrease of at least 4 points on the estimated ADAS-cog scores as cutoff criterion for treatment response, 35 % of EGb 761®-treated patients were considered responders versus only 19 % for the placebo group (P = 0.01). The results of this ITT analysis substantiate the outcomes previously obtained with a responder analysis of the per-protocol population and confirm that EGb 761® improves cognitive function in a clinically relevant manner in patients suffering from dementia. The therapeutic effect is in line with the outcome of another EGb 761® study conducted in the U.S. [16] [17].

References

• 1 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (3rd ed. rev.) DSM-III-R. Washington, DC; American Psychiatric Association 1987
  Google Scholar
• 2 Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H J,. et al . The effects of donepezil in Alzheimer’s disease - Results from a multinational trial.  Dement Geriatr Cogn Disord. 1999;  10 237-244
  CrossrefPubMedGoogle Scholar
• 3 CPMP - Committee for Proprietary Medicinal Products. Note for guidance on medicinal products in the treatment of Alzheimer’s disease. London; The European Agency for the Evaluation of Medicinal Products 1997
  Google Scholar
• 4 Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study G roup. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease.  Int J Geriatr Psychopharmacol. 1998;  1 55-65
  PubMedGoogle Scholar
• 5 Davis L K, Thal L J, Gamzu E R. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease.  N Engl J Med. 1992;  327 1253-1259
  CrossrefPubMedGoogle Scholar
• 6 Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju C V. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial.  Lancet. 2002;  359 1283-1290
  CrossrefPubMedGoogle Scholar
• 7 Erzigkeit H. Manual zum SKT Formen A-E. Ebersberg; Vless 1986
  Google Scholar
• 8 Folstein M F, Folstein S E, McHugh P R. „Mini-mental-state”. A practical method for grading the cognitive state of patients for the clinician.  J Psychiat Res. 1975;  12 189-198
  CrossrefPubMedGoogle Scholar
• 9 Gutzmann H, Kühl K P, Hadler D, Rapp M A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: Results of a randomized, double-blind, parallel-group multicenter study.  Pharmacopsychiatry. 2002;  35 12-18
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Hemmeter U, Annen B, Bischof R, Brüderlin U, Hatzinger M, Rose U, Holsboer-Trachsler E. Polysomnographic effects of adjuvant Ginkgo biloba therapy in patients with major depression medicated with trimipramine.  Pharmacopsychiatry. 2001;  34 50-59
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Ihl R, Grass-Kapanke B, Jänner M, Weyer G. Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS-cog, SKT and MMSE.  Pharmacopsychiatry. 1999;  32 248-354
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Itil T M, Eralp E, Tsambis E, Itil K Z, Stein U. Central nervous system effects of Ginkgo biloba, a plant extract.  Am J Therapeut. 1996;  3 63-73
  PubMedGoogle Scholar
• 13 Kanowski S, Ladurner G, Maurer K, Oswald W D, Stein U. Empfehlungen zur Evaluierung der Wirksamkeit von Nootropika.  Z Gerontopsychol -psychiat. 1990;  3 67-79
  PubMedGoogle Scholar
• 14 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hörr R. Proof of efficacy of the Ginkgo biloba extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.  Pharmacopsychiatry. 1996;  29 47-56
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Knopman DS; Knapp MJ; Gracon S I, Davis C S. The clinician interview-based impression (CIBI).  Neurol. 1994;  44 2315-2321
  PubMedGoogle Scholar
• 16 Le Bars P L., Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg A F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia.  JAMA. 1997;  278 1327-1333
  CrossrefPubMedGoogle Scholar
• 17 Le Bars P L, Kieser M, Itil K Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761® in Dementia.  Dement Geriatr Cogn Disord. 2000;  11 230-237
  CrossrefPubMedGoogle Scholar
• 18 Leber P. Global assessment measures. Letter to sponsors. Rockville; US Food and Drug Administration; undated
  Google Scholar
• 19 Mohs R C, Rosen W G, Davis K L. The Alzheimer’s Disease Assessment Scale: an instrument for assessing treatment efficacy.  Psychopharmacol Bull. 1983;  19 448-450
  PubMedGoogle Scholar
• 20 Montgomery S and Asberg M. A new depression scale designed to be sensitive to change.  Br J Psychiat. 1979;  134 382-389
  CrossrefPubMedGoogle Scholar
• 21 Morich F J, Bieber F, Lewis J M. Nimodipine in the treatment of probable Alzheimer’s disease.  Clin Drug Invest. 1996;  11 185-195
  PubMedGoogle Scholar
• 22 National Institute of Mental Health. CGI, Clinical Global Impressions. In Guy E, editor ECDEU Assessment Manual for Psychopharmacology. Rockville, Maryland; National Institute of Mental Health 1986: p. 217-222
  Google Scholar
• 23 Oswald W D, Fleischmann U M. Nürnberger-Alters-Inventar (NAI: Nuremberg Gerontopsychological Inventory). Nürnberg; Universität Erlangen-Nürnberg, Psychologisches Institut II 1986
  Google Scholar
• 24 Overall J E, Schaltenbrand R. The SKT neuropsychological test battery.  J Geriatr Psychiatry Neurol. 1992;  5 220-227
  PubMedGoogle Scholar
• 25 Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin H B, Hartman R, Gharabawi M, on behalf of the B303 Exelon Study G roup. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial.  BMJ. 1999;  318 633-640
  PubMedGoogle Scholar
• 26 Rogers S l, Farlow M R, Doody R S, Mohs R, Friedhoff LT and the Donepezil Study G roup. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease.  Neurology. 1998;  50 136-145
  CrossrefPubMedGoogle Scholar
• 27 Rosen W G, Terry R D, Fuld P D, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias.  Ann Neurol. 1980;  7 486-488
  CrossrefPubMedGoogle Scholar
• 28 Schneider L S, Olin J T, Doody R S, Clar C M, Morris J C, Reisberg B ,. et al . Validity and reliability of the Alzheimer’s Disease Cooperative Study - Clinical Global Impression of Change.  Alzheimer Dis Assoc Disord. 1997;  11 Suppl 2 S22-32
  PubMedGoogle Scholar
• 29 Schwartz G E. Development and validation of the Geriatric Evaluation by Relative’s Rating Instrument (GERRI).  Psychol Reports. 1983;  53 479-488
  PubMedGoogle Scholar
• 30 Weyer G, Eul A, Milde K, Wierich W, Herrmann W M. Cynlandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: Experience from a placebo controlled multi-center study.  Pharmacopsychiatry. 2000;  33 89-97
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Wilcock G K, Lilienfeld S, Gaens E on behalf of the Galantamine International-1 Study G roup. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial.  Br Med J. 2000;  321 1445-1449
  CrossrefPubMedGoogle Scholar

Dr. med. Robert Hoerr

Leiter Geriatrie/ZNS

Dr. Willmar Schwabe GmbH & Co.

Willmar-Schwabe-Straße 4

76227 Karlsruhe